

Artificial activation of *Escherichia coli mazEF* and *hipBA* toxin-antitoxin systems by antisense peptide nucleic acids as an antibacterial strategy

Marcin Równicki^{1,2}, Tomasz Pieńko^{1,3}, Jakub Czarnecki^{4,5}, Monika Kolanowska^{1,6}, Dariusz Bartosik⁴, Joanna Trylska^{1*}

¹Centre of New Technologies, University of Warsaw, Banacha 2c, 02-097 Warsaw, Poland

²College of Inter-Faculty Individual Studies in Mathematics and Natural Sciences, University of Warsaw, Banacha 2c, 02-097 Warsaw, Poland


³Department of Drug Chemistry, Faculty of Pharmacy with the Laboratory Medicine Division, Medical University of Warsaw, Banacha 1a, 02-097 Warsaw, Poland

⁴Department of Bacterial Genetics, Institute of Microbiology, Faculty of Biology, University of Warsaw, Miecznikowa 1, 02-096, Warsaw, Poland


⁵Unit of Bacterial Genome Plasticity, Department of Genomes and Genetics, Institute Pasteur, 25-28 rue du Dr Roux, 75015 Paris, France

⁶Genomic Medicine, Medical University of Warsaw, Banacha 1a, 02-097 Warsaw, Poland


*** Correspondence:** Joanna Trylska: joanna@cent.uw.edu.pl



Supplementary Figure 1. No growth inhibition of *E. coli* strains after 20 h incubation with a) PNAnc and b) ($\text{KFF})_3\text{K}$ peptide. Error bars represent the standard error of the mean of 3 replicates. The differences between corresponding samples are not significant ($P > 0.05$).



Supplementary Figure 2. No growth inhibition of *E. coli* strains lacking toxin genes after 20 h incubation with the corresponding PNAs. Error bars represent the standard error of the mean. The differences between 0 μM and 16 μM at 20 h for *E. coli* $\Delta mazF$ are not significant ($P > 0.05$) and for *E. coli* $\Delta hipA$ are significant ($P < 0.01$).



Supplementary Figure 3. The effect of treatment with PNAs on the level of toxin mRNA transcripts in *E. coli* K-12. The graph shows the relative fold change in expression compared to untreated control samples. Error bars represent the mean \pm SEM, n=2.

Supplementary Table 1. Bacterial strains used in this study.

Strains	Relevant characteristics	Reference
<i>E. coli</i> K-12 MG1655	F ⁻ λ ⁻ wild-type strain	(Guyer et al., 1981)
<i>E. coli</i> 0157:H7 ST2-8624	(Δ <i>stx2::cat gfp</i>)	(Łoś et al., 2008)
<i>E. coli</i> WR3551/98	<i>bla</i> _{CTX-M-15} ESBL+	(Baraniak, 2002)
<i>E. coli</i> DH5αλpir	F- Δ <i>lacU169</i> (Φ <i>lacZΔM15</i>), <i>recA1</i> , <i>endA1</i> , <i>hsdR17</i> , <i>thi-1</i> , <i>gyrA96</i> , <i>relA1</i> , λpir+	(Platt et al., 2000)
<i>E. coli</i> β2163	MG1655:: Δ <i>dapA::(erm-pir)RP4-2-Tc::Mu [Km^R]</i>	(Demarre et al., 2005)
<i>E. coli</i> K-12 MG1655 Δ <i>mazF</i>	MG1655 (Δ <i>mazF::kan</i>)	This study
<i>E. coli</i> JW1500-2 Δ <i>hipA</i>	Δ <i>hipA728::kan</i>	(Baba et al., 2006)

Supplementary Table 2. Oligonucleotide primers used in this study.



Name	Sequence (5' → 3')	Application
pds132X	CCCATGTCAGCCGTTAAGTG	construction of a cassette for deletion of <i>mazF</i>
pds132Y	ATCGCGGGTTGTTACTG	
mazF1	CAGTAACAAACCCGCGATCTACTCCGCCG GATATTGC	
mazF2	AGAGATTGAGACACAACGGATGCCATA TCGGGTACG	
mazF3	TAATTGGTTGTAACACTGGCAGAGGAGAAC GAAGAAAGG	
mazF4	CACTAACGGCTGACATGGCAAGCGTCGTC CAATCGAAG	
KML	CGTTGTGTCTAAAATCTCT	confirmation of <i>mazF</i> deletion
KMR	GCCAGTGTACAACCAATT	
LmazFspr	CAAGCGTCGTCATCGAAG	RT-qPCR for <i>mazE</i> transcript
RmazFspr	GGCGCGGTATTCAGTACAC	
mazE_F1	AAGCGTTGGGGAAATTCAACC	RT-qPCR for <i>mazF</i> transcript
mazE_R1	AATTGCCATCCACCAGGTC	
mazF_F1	ACAAAAGGTAGCGAGCAAGC	RT-qPCR for <i>thyA</i> transcript
mazF_R1	GCGTTGTACAAGGAACACACAG	
thyA_F1	GGCCAGTGTATGGTAAACAG	RT-qPCR for <i>hipB</i> transcript
thyA_R1	TATCCAGTTCGCCTACGTTTC	
hipB_F1	TTAAGCAGGCGACGATTCC	RT-qPCR for <i>hipA</i> transcript
hipB_R1	TTCTGGCGAGGCATTTTCG	
hipA_F1	TGGCGAAAGAACTTGGTTG	RT-qPCR for <i>gltX</i> transcript
hipA_R1	AACGCCGTCAAAACGTTCG	
gltX_F1	CGTTTGATCGCTACACGC	RT-qPCR for <i>gyrA</i> transcript (reference)
gltX_R1	TTTCGCCATTGCTCTTCGC	
gyrA_F1	TGGAAGTTGACGCCAAACC	amplification of <i>mazE</i> gene for DNA sequencing
gyrA_F2	ATGCCTCCACCGCTTTTC	
mazEF-For	GCAGGCGCTGCATAATAGTG	
mazEF-Rev	TGCGCCAGAACGCATTGTTG	

hipBA-For	GCTGTCTGCCCTATTCCTG	amplification of <i>hipB</i> gene for DNA sequencing
hipBA-Rev	CGCCGTGAAGATGAATGGTC	
gltX-For	TAGAAACGTGCGCGTAAACC	amplification of <i>gltX</i> gene for DNA sequencing
gltX-Rev	ACGGCGGAGACTACATAAAG	
thyA-For	TGCTGCGCCATCATATGCAC	amplification of <i>thyA</i> gene for DNA sequencing
thyA-Rev	CGCACCACTCATTCCGTTG	


Supplementary Table 3. Retention times (tR) and molecular masses of the synthesized conjugates.

^aThe product was analyzed by RP-HPLC. To increase water solubility, each PNA has a lysine at the C-terminus.

Nr	Compound	Short name	HPLC tR ^a [min]	HPLC method	Molecular mass [g/mol]	
					Calculated	Detected
1	(KFF) ₃ K-AEEA-PNA anti- <i>mazE</i> -K	anti- <i>mazE</i> PNA	9.0	26-29% ACN 30 min	4833.17	4832
2	(KFF) ₃ K-AEEA-PNA anti- <i>thyA</i> -K	anti- <i>thyA</i> PNA	13.3	25-32% ACN 30 min	4880.17	4879.5
3	(KFF) ₃ K-AEEA-PNA anti- <i>hipB</i> -K	anti- <i>hipB</i> PNA	24.9	0-50% ACN 30 min	4646.87	4646.25
4	(KFF) ₃ K-AEEA-PNA anti- <i>gltX</i> -K	anti- <i>gltX</i> PNA	20.7	0-50% ACN 30 min	4401.67	4401.5
5	(KFF) ₃ K-AEEA-PNAnc-K	PNAnc	12.7	25-35% ACN 30 min	4880.17	4879.5


(KFF)₃K-AEEA-PNA anti-*mazE*-K**Supplementary Figure 4.** Mass spectrum and HPLC chromatogram for (KFF)₃K-AEEA-PNA anti-*mazE*-K**(KFF)₃K-AEEA-PNA anti-*thyA*-K****Supplementary Figure 5.** Mass spectrum and HPLC chromatogram for (KFF)₃K-AEEA-PNA anti-*thyA*-K

(KFF)₃K-AEEA-PNA anti-*hipB*-K




Supplementary Figure 6. Mass spectrum and HPLC chromatogram for (KFF)₃K-AEEA-PNA anti-*hipB*-K

(KFF)₃K-AEEA-PNA anti-*gltX*-K



Supplementary Figure 7. Mass spectrum and HPLC chromatogram for (KFF)₃K-AEEA-PNA anti-*gltX*-K

(KFF)₃K-AEEA-PNAc-K**Supplementary Figure 8.** Mass spectrum and HPLC chromatogram for (KFF)₃K-AEEA-PNAc-K**References:**

- Baba, T., Ara, T., Hasegawa, M., Takai, Y., Okumura, Y., Baba, M., et al. (2006). Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: The Keio collection. *Mol. Syst. Biol.* 2. doi:10.1038/msb4100050.
- Baraniak, A. (2002). Ceftazidime-hydrolysing CTX-M-15 extended-spectrum beta-lactamase (ESBL) in Poland. *J. Antimicrob. Chemother.* 50, 393–396. doi:10.1093/jac/dkf151.
- Demarre, G., Guérout, A. M., Matsumoto-Mashimo, C., Rowe-Magnus, D. A., Marlière, P., and Mazel, D. (2005). A new family of mobilizable suicide plasmids based on broad host range R388 plasmid (IncW) and RP4 plasmid (IncP α) conjugative machineries and their cognate Escherichia coli host strains. *Res. Microbiol.* 156, 245–255. doi:10.1016/j.resmic.2004.09.007.
- Guyer, M. S., Reed, R. R., Steitz, J. A., and Low, K. B. (1981). Identification of a sex-factor-affinity site in E. coli as gamma delta. *Cold Spring Harb. Symp. Quant. Biol.* 45, 135–140. doi:10.1101/SQB.1981.045.01.022.
- Łoś, J. M., Golec, P., Węgrzyn, G., Węgrzyn, A., and Łoś, M. (2008). Simple method for plating Escherichia coli bacteriophages forming very small plaques or no plaques under standard conditions. *Appl. Environ. Microbiol.* 74, 5113–5120. doi:10.1128/AEM.00306-08.
- Platt, R., Drescher, C., Park, S. K., and Phillips, G. J. (2000). Genetic system for reversible integration of DNA constructs and lacZ gene fusions into the Escherichia coli chromosome. *Plasmid* 43, 12–23. doi:10.1006/plas.1999.1433.